Skip to content
OpenCapital
Get started

Haemonetics HAE Debt Instrument, Convertible, Capped Call Transaction, Anti-Dilution Adjustment, Shares

Other financials

Income statement

See full
Revenue$346.4M+4.8%
Gross profit$198.2M+2.7%
Operating income$67.4M+14.2%
Net income$44.7M+19.3%
EPS (diluted)$0.95+28.4%

Balance sheet

See full
Cash & equivalents$245.4M-20.0%
Total debt$1.3B-0.7%
Total equity$796.3M-3.0%
Total assets$2.4B-2.2%

Cash flow

See full
Operating cash flow$70.9M-39.1%
CapEx$17.7M+12.9%
Free cash flow$53.3M-47.2%

Valuation

See full
Market cap$3.31B-18.0%

Profitability

See full
Gross margin59%+4.0pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin19.5%+9.1pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.6×0.0×
Current ratio3×+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept hae:DebtInstrumentConvertibleCappedCallTransactionAntiDilutionAdjustmentShares.

The official record: Haemonetics’s 10-Q, filed February 5, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Haemonetics's debt instrument, convertible, capped call transaction, anti-dilution adjustment, shares?
Haemonetics (HAE) reported debt instrument, convertible, capped call transaction, anti-dilution adjustment, shares of 6M in Q2 2024.